Algert Global LLC Increases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Algert Global LLC boosted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 193.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 147,218 shares of the biopharmaceutical company’s stock after acquiring an additional 97,118 shares during the quarter. Algert Global LLC owned 0.10% of TG Therapeutics worth $2,619,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the stock. Ashton Thomas Private Wealth LLC purchased a new stake in shares of TG Therapeutics during the second quarter worth about $35,000. DekaBank Deutsche Girozentrale purchased a new stake in TG Therapeutics during the 1st quarter worth approximately $58,000. nVerses Capital LLC raised its holdings in shares of TG Therapeutics by 34.9% during the second quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,500 shares during the last quarter. Lazard Asset Management LLC purchased a new position in shares of TG Therapeutics in the first quarter valued at approximately $91,000. Finally, Headlands Technologies LLC acquired a new stake in shares of TG Therapeutics in the second quarter worth approximately $124,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $22.83 on Wednesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The company has a market capitalization of $3.53 billion, a PE ratio of 99.26 and a beta of 2.21. The firm’s 50-day moving average is $22.37 and its two-hundred day moving average is $18.70. TG Therapeutics, Inc. has a 12 month low of $6.46 and a 12 month high of $26.41.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.08. The firm had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.92 million. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The business’s revenue for the quarter was up 357.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.34) EPS. Analysts predict that TG Therapeutics, Inc. will post 0.13 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on TGTX shares. B. Riley raised their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. The Goldman Sachs Group boosted their price target on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $49.00 price objective on shares of TG Therapeutics in a report on Wednesday, September 18th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.83.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.